Skip to main content
Premium Trial:

Request an Annual Quote

Sclero-Smart

Specialty biotech firm Gemelli Biotech has launched Sclero-Smart, a blood-based test that measures levels of anti-vinculin, an autoantibody which has been found to be elevated in sclerodema patients and associated with gastrointestinal complications. The finding of the association suggests a link between sclerodema and the gut microbiome, the Los Angeles-based firm said, and could lead to new microbiome-related diagnostic tools and therapeutics for the disease. The Sclero-Smart, which uses an ELISA format measures anti-vinculin levels in patients with systemic sclerosis and sclerodema.